Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...198199200201202203204205206207208...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, PD(L)-1 Biomarker, IO biomarker:  Dual "unlocking" strategy to overcome inefficient nanomedicine delivery and tumor hypoxia for enhanced photodynamic-immunotherapy. (Pubmed Central) -  Mar 2, 2023   
    Herein, a dual "unlocking" strategy to overcome these obstacles is proposed by combining engineered hybrid nanoparticles (named ZnPc@FOM-Pt) with dexamethasone (DXM)...Moreover, the immunosuppressive tumor microenvironment is efficiently reversed and the therapeutic effect of anti-PD-L1-based immunotherapy is promoted by this newly designed nanomedicine. This dual "unlocking" strategy provides an innovative paradigm on simultaneously enhancing nanomedicine delivery efficacy and hypoxia relief for tumor therapy.
  • ||||||||||  Review, Journal:  SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature. (Pubmed Central) -  Mar 2, 2023   
    Dexamethasone has been shown to improve outcomes in non-SCD patients with severe acute respiratory syndrome-corona virus-2 pneumonia or acute respiratory distress syndrome; however, its use in SCD patients with ACS is controversial due to a reported increased risk of complications including vaso-occlusive painful episodes...Packed red blood cell transfusion (n=11), exchange transfusion (n=4), or a combination of exchange transfusion and packed red blood cell transfusion (n=4) were the most frequently reported treatment, with hydroxychloroquine (n=5), remdesivir (n=1), and tocilizumab (n=1) also being reported...Even though transfusion is considered the standard of care for children with ACS and steroids are not routinely recommended, our experience suggested that COVID-19-associated ACS may be an important exception, especially for patients who refuse transfusion or are in resource-poor nations where blood transfusions may not be readily available. Further studies are warranted to confirm these observations.
  • ||||||||||  triamcinolone acetonide / Generic mfg., Triesence (triamcinolone acetonide injectable suspension) / Novartis, Avastin (bevacizumab) / Roche
    Journal:  Coats disease in India: clinical presentation and outcome in 675 patients (690 Eyes). (Pubmed Central) -  Mar 2, 2023   
    The most common clinical presentation of Coats disease in India is foveal exudation in first and second decade. At initial presentation, about half of the affected eyes had blindness and one-third underwent surgical intervention.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection (clinicaltrials.gov) -  Mar 2, 2023   
    P4,  N=41, Terminated, 
    No abstract available N=102 --> 41 | Trial completion date: Dec 2024 --> Feb 2023 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2023 --> Feb 2023; recruitment and staffing
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    New P2/3 trial, Surgery:  Use of Corticosteroids in Third Molar Surgery (clinicaltrials.gov) -  Mar 2, 2023   
    P2/3,  N=84, Recruiting, 
  • ||||||||||  cefazolin / Generic mfg., dexamethasone / Generic mfg.
    Journal:  Influence of discontinuation of prophylactic antimicrobial agent for trabeculectomy. (Pubmed Central) -  Mar 1, 2023   
    It can also be used as an enhancer for classic anti-inflammatory drugs. There was no significant difference in the incidence of endophthalmitis after trabeculectomy between the CEZ and non-CEZ groups, suggesting a decreased need for CEZ injections before trabeculectomy.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Trial completion date, Trial primary completion date:  Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2 (clinicaltrials.gov) -  Mar 1, 2023   
    P3,  N=200, Not yet recruiting, 
    Trial primary completion date: Sep 2022 --> Feb 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis (clinicaltrials.gov) -  Mar 1, 2023   
    P1,  N=210, Recruiting, 
    Trial completion date: Sep 2029 --> Dec 2029 | Trial primary completion date: Sep 2029 --> Dec 2029 Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Enrollment closed, Combination therapy:  REST - Replacing Steroids in the Transplant Ineligble (clinicaltrials.gov) -  Mar 1, 2023   
    P2,  N=51, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Enrollment closed, Enrollment change:  Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) -  Mar 1, 2023   
    P1,  N=47, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=100 --> 47
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  The Bovine Herpesvirus 1 Latency-Reactivation Cycle, a Chronic Problem in the Cattle Industry. (Pubmed Central) -  Mar 1, 2023   
    More sophisticated estimation procedures, such as treatment effect models, are necessary to obtain conclusive results. Glucocorticoids, including the synthetic corticosteroid dexamethasone, are major effectors of the stress response...These receptors form feed-forward transcription loops with the stress-induced Kr
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Live Triple Gene-Deleted Pseudorabies Virus-Vectored Subunit PCV2b and CSFV Vaccine Undergoes an Abortive Replication Cycle in the TG Neurons following Latency Reactivation. (Pubmed Central) -  Mar 1, 2023   
    Based on nasal virus shedding, immediate early (infected cell protein 0; ICP0) and late genes, MCP (major capsid protein) and gC (glycoprotein C) transcriptions, and viral DNA copy numbers in the TGs of latently infected and dexamethasone (Dex)-treated pigs, both PRV wt and PRVtmv+ reactivated from latency...Our results demonstrated that the PRVtmv+ is safe as a live viral subunit vaccine vector without the possibility of productive replication in the TG upon reactivation from latency and without subsequent nasal virus shedding. This property of PRVtmv+ precludes the possibility of vaccine virus circulation in pigs and the risk of reversion to virulence.
  • ||||||||||  dexamethasone / Generic mfg.
    Retrospective data, Journal:  Non-Dexamethasone Corticosteroid Therapy's Effect on COVID-19 Prognosis in Cancer Patients: A Retrospective Study. (Pubmed Central) -  Mar 1, 2023   
    Despite the limited sample size, H- and P-treated patients' corticosteroids performed worse than the control, especially if treatments were received after COVID-19 infection. Hence, when a cancer patient already on H or P treatment is diagnosed with COVID-19, we recommend switching to a steroid treatment as suggested by international guidelines.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma, AIRZ-FF (glycopyrrolate/formoterol fumarate/fluticasone propionate) / Glenmark
    Journal:  Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD. (Pubmed Central) -  Feb 28, 2023   
    Hence, when a cancer patient already on H or P treatment is diagnosed with COVID-19, we recommend switching to a steroid treatment as suggested by international guidelines. Our results showed that SITT significantly improved the IC, %IC, FVC, and %FEV when compared to pre-intervention and that F/U/V was more effective in subjects with severe symptoms, whereas B/G/F was more effective in subjects with mild symptoms.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. (Pubmed Central) -  Feb 28, 2023   
    P3
    In this small, open-label, randomised trial of non-critically ill hospitalised patients with COVID-19, the combination of colchicine and rosuvastatin in addition to standard of care did not appear to reduce the risk of progression of COVID-19 disease or thromboembolic events, although the trial was underpowered due to a lower-than-expected event rate. The trial leveraged the power of electronic medical records for efficiency and improved follow-up and demonstrates the utility of incorporating electronic medical records into future trials.